Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Retrospective Analysis of 23 Patients

Objective: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are dermatologic emergencies. There is a lack of consensus regarding appropriate management of SJS/TEN. The aim of this study was to evaluate demographic and clinical features, management and outcomes of SJS/TEN patients. Materials and Methods: The data of patients who were ≥18 years old and hospitalized with the diagnosis of SJS, SJS-TEN overlap and TEN at Hacettepe University, between 1992 and 2018 were analyzed retrospectively. Patient demographics, medications, time between the first causative drug intake and the onset of symptoms, mucous membrane involvement, treatment modalities including supportive measures, intravenous immunoglobulin, cyclosporine and systemic corticosteroids, duration of hospitalization, and mortality outcomes were recorded from patient charts. Results: A total of 23 patients (11 men; 12 women) with a mean age of 46.4 ± 19.5 years were included in the study. Twelve patients (52.2%) had SJS, 8 patients (34.8%) had SJS/TEN overlap and 3 patients (13%) had TEN. Mean duration of hospitalization was 12.6 ± 6.5 days. Twenty-two patients (95.7%) were attributed to a specific medication, whereas triggering factor was not detected in 1 patient (4.3%). More than one drug was responsible for 9 patients, including antimicrobials (n=11, 47.8%), anticonvulsants (n=8, 34.8%) and/or non-steroid antiinflammatory drugs (n=5, 21.7%). The median time between the intake of medication and the onset of symptoms was 20 days (IQR 5.5-30). Sixteen patients used systemic corticosteroids (69.6%) and 4 patients used intravenous immunoglobulin (17.4%) whereas 3 patients used systemic corticosteroids in combination with intravenous immunoglobulin (n=2, 8.7%) or cyclosporin (n=1, 4.3%). The median time between the onset of symptoms and the onset of the rash to the treatment was 5 days (IQR 3-7). Mortality was not observed in our cohort. Conclusion: SJS/TEN was most commonly developed because of drugs, mainly antimicrobials, anticonvulsants and/or non-steroid anti-inflammatory drugs. The absence of mortality in our cohort was considered to be associated with younger age, low rate of TEN, prompt initiation of treatment (mainly corticosteroids) following the rapid discontinuation of the suspected drug.

___

[1] Bastuji-Garin S, Rzany B, Stern RS et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92-6.

[2] Micheletti RG, Chiesa-Fuxench Z, Noe MH et al. StevensJohnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. J. Invest Dermatol. 2018;138(11):2315- 2321.

[3] Lee HY, Walsh SA, Creamer D. Long-term complications of Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up. Br J Dermatol. 2017;177(4):924-935.

[4] Bastuji-Garin S., Fouchard N, Bertocchi M. et al. SCORTEN: A Severity-of-Illness Score for Toxic Epidermal Necrolysis. J Invest Dermatol 2000;115:149-153.

[5] Schneck J, Fagot J.P., Sekula P. et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008;58:33-40.

[6] Chung W.H., Wang C.W., and Dao R.L et al. Severe cutaneous adverse drug reactions. J Dermatol. 2016;43(7):758-66.

[7] Sassolas B, Haddad C, Mockenhaupt M. et al. ALDEN, an algorithm for assessment of drug causality in stevensjohnson syndrome and toxic epidermal necrolysis: Comparison with case-control analysis. Clin. Pharmacol. Ther. 2010;88(1):60-8.

[8] Dodiuk-Gad R.P., Chung WH, L. Valeyrie-Allanore L. et al. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: An Update. Am J Clin Dermatol. 2015;16(6):475- 93.

[9] Hung SI, Chung WH, Liou LB. et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci USA. 2005;102(11):4134-9.

[10] J C Roujeau JC, Kelly JP, Naldi L et al. Medication Use and the Risk of Stevens–Johnson Syndrome or Toxic Epidermal Necrolysis. N Engl J Med. 1995;333(24):1600-7.

[11] Samimi S.S. and Siegfried E. Stevens-Johnson syndrome developing in a girl with systemic lupus erythematosus on high-dose corticosteroid therapy. Pediatr Dermatol. JanFeb 2002;19(1):52-5.

[12] Lee EC, Kim GA, Koo JW. Toxic epidermal necrolysis associated with deflazacort therapy with nephrotic syndrome. Kidney Res Clin Pract. 2014;33(4):222-5.

[13] Trujillo-Trujillo MJ, González-Mancebo E, GandolfoCano M. et al. Deflazacort-induced erythema multiforme exudativum successfully treated with a single dose of etanercept. J Investig Allergol Clin Immunol. 2018;28(5):338-339.

[14] Mockenhaupt M, Viboud C, Dunant A. et al.StevensJohnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol. 2008;128(1):35-44.

[15] Kim PS, GoldfarbI W, Gaisford JC, et al. Stevens±Johnson syndrome and toxic epidermal necrolysis: a pathophysiologic review with recommendations for a treatment protocol. J Burn Care Rehabil. 1983;4:91-100.

[16] Halebian PH, Corder VJ, Madden MR. et al. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg. 1986;204:512–513.

[17] Sekula P, Dunant A., Mockenhaupt M. et al.Comprehensive survival analysis of a cohort of patients with StevensJohnson syndrome and toxic epidermal necrolysis. J. Invest Dermatol. 2013;133(5):1197-1204.

[18] Hirahara K.Kano Y. Sato Y et al. Methylprednisolone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis: Clinical evaluation and analysis of biomarkers. J. Am. Acad. Dermatol.2013;69(3):496-498.

[19] Kardaun SH, and Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2007;87(2):144-8.

[20] Roongpisuthipong W., Prompongsa S, Klangjareonchai T.Retrospective analysis of corticosteroid treatment in Stevens-Johnson syndrome and/or toxic epidermal necrolysis over a period of 10 years in Vajira Hospital, Navamindradhiraj University, Bangkok. Dermatol Res Pract. 2014; 2014:237821.

[21] Valeyrie-Allanore L, Wolkenstein P, Brochard L et al. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol. 2010;163(4):847-53.

[22] Kirchhof MG, Miliszewski MA, Sikora S et al. Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. J Am Acad Dermatol. 2014;71(5):941-7.

[23] Olteanu C, Shear NH, Burnett M. et al. Retrospective Study of Patients With SJS/TEN Treated at a Tertiary Burn Unit in Canada: Overview of 17 Years of Treatment. J Cutan Med Surg. 2021;25(3):271-280.

[24] Tsai TY, Huang IH, Chao YC et al. Treating toxic epidermal necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis. J Am Acad Dermatol. 2021;84(2):390-397.
Acta Medica-Cover
  • ISSN: 2147-9488
  • Yayın Aralığı: Yılda 4 Sayı
  • Başlangıç: 2012
  • Yayıncı: HACETTEPE ÜNİVERSİTESİ
Sayıdaki Diğer Makaleler

The Inflammatory Processes Driven by Gut Microbiota

Ayşe BURUŞ, Başak ÇELTİKÇİ, Yasemin AKSOY

The Effectiveness of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in Patients With Undiagnosed Lung Cancer

Elif Yelda NİKSARLIOĞLU, Şule GÜL, Ayşe YETER

The Comparison of ISUP Grades Between Prostate Biopsy and Radical Prostatectomy: The Incoherence and Related Factors

Bülent ÖZTÜRK, Erman CEYHAN, Burak YILMAZ

COVID-19 Associated Refractory Immune Thrombocytopenia: A Case Report

Pusem PATIR

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Retrospective Analysis of 23 Patients

Başak Yalıc ARMAĞAN, Caner DEMİRCAN, Neslihan AKDOĞAN, Duygu GÜLSEREN, Sibel DOĞAN, Gonca ELÇİN, Sibel ERSOY EVANS

Henoch Schönlein Purpura / Ig A Vasculitis in Children and Risk Factors for Renal Involvement

Selcan DEMİR, Müferret ERGÜVEN, Cengiz CANDAN, Pınar TURHAN

In-Silico Analysis of The Correlation Between PD-L1 and ProInflammatory Type Interleukins and The Distribution of Their Potential Primary Sources in KRAS-Mutated Non-Small Cell Lung Carcinoma

Neşe ÜNVER

Pediatric Liver Transplantation as Enzyme Replacement Therapy for Rare Metabolic Diseases with No Structural Liver Damage

Neslihan ÇELİK, Remzi EMİROĞLU

Utilization of Synthetic Hematocrit Derived from Cardiac MRI for Estimating Extracellular Volume

Ahmet Gürkan ERDEMİR, Tuncay HAZIROLAN, Ekim GÜLER, Osman ÖCAL

Ranking of Everyday Activities by Risk of Coronavirus in the Istanbul Metropolitan Area, Turkey

Ümit KARTOĞLU, Deniz NALA KURTUOĞLU, LEVENT EKER, Hamza ÖZDEMİR, Ayşe Nilüfer ÖZAYDIN